Drug Trial Radar · NCT00819585
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
Last checked: Nov 20, 2026Latest source record: Jul 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
432
Actual
Start
Dec 2008
Primary completion
Aug 2010
Study completion Aug 2010
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout flare.
Conditions
- Gout
Interventions
CanakinumabDrug
Canakinumab was supplied in glass vials as a lyophilized powder.
ColchicineDrug
0.5 mg capsule orally once daily for 16 weeks.
AllopurinolDrug
100-300 mg orally once daily for 24 weeks.
Placebo Matching CanakinumabDrug
Subcutaneous injection.
Placebo Matching ColchicineDrug
Capsule orally once daily for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study: Mean Number of Gout Flares Per ParticipantTime frame: Baseline of the core study to Week 16
Locations
89 sites in 18 countries. Site status is shown where the registry gives one.
Talbert Medical Group
Huntington Beach, California
San Diego Arthritis & Osteoporosis Medical clinic
San Diego, California
Health Awareness
Jupiter, Florida
East-West Medical Research institute
Honolulu, Hawaii
Pinnacle Medical Research
Overland Park, Kansas
Cotton O'Neil Clinical Research Institute
Topeka, Kansas
Dolby Research, LLC
Baton Rouge, Louisiana
The Family Doctors
Shreveport, Louisiana
Shores Rheumatology
Saint Clair Shores, Michigan
Heartland Clinical Research, Inc.
Omaha, Nebraska
NM Clinical Research & Osteoporosis Ct.
Albuquerque, New Mexico
Rochester clinical Research
Rochester, New York
Health Research of Oklahoma, PLLC
Oklahoma City, Oklahoma
Castlerock Clinical Research Consultants, LLC
Tulsa, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Columbia Clinical Research
Columbia, South Carolina
Upstate Pharmaceutical Research
Greenville, South Carolina
MultiSpecialty Clinical Research
Johnson City, Tennessee
iMED Internal medicine, PA
San Antonio, Texas
Novartis Investigative site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative site
Rosario, Argentina
Novartis Investigative Site
Gozée, Belgium
Novartis Investigative site
Oostham, Belgium
Novartis Investigative Site
Bacaramanga, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Fundación Cardiovascular de Colombia
Florida Blanca, Colombia
Novartis Investigative site
Havířov, Czechia
Novartis Investigative site
Ostrava, Czechia
Novartis Investigative site
Pardubice, Czechia
Novartis Investigative site
Uherské Hradiště, Czechia
Novartis Investigative site
Zlín, Czechia
Novartis Investigative Site
Bautzen, Germany
Novartis Investigative Site
Chemnitz, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Georgensgmünd, Germany
Novartis Investigative Site
Göttingen, Germany
Novartis Investigative Site
Hamburg, Germany
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.